Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
iPRRT Study: Pembrolizumab + Lutetium Lu 177 Dotatate in Merkel Cell Cancer
NCT05583708Phase 2Recruiting
- Sponsor
- Weill Cornell Medicine
- Start
- Aug 2023
- Primary completion
- Dec 2028
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of lutetium Lu 177 dotatate in Merkel cell carcinoma (MCC), sponsored by Weill Cornell Medicine. Primary endpoint: Objective Response Rate at 2 years. Started Aug 2023; status: recruiting.
02
Drugs
lutetium Lu 177 dotatate
03
Conditions
Merkel cell carcinoma (MCC)
Beyond the preview
Go deeper on NCT05583708.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05583708.